Show simple item record

Treatment with Epinastine Hydrochloride to 0.05 % in Patients with Moderate Tear Dysfunction Syndrome

dc.creatorCarrizosa Murcia, Marcelospa
dc.creatorRodríguez Álvarez, Martha Fabiolaspa
dc.date2012-07-12spa
dc.date.accessioned2017-06-12T20:10:30Zspa
dc.date.available2017-06-12T20:10:30Zspa
dc.identifierhttp://revistas.lasalle.edu.co/index.php/sv/article/view/94spa
dc.identifier10.19052/sv.94spa
dc.identifier.urihttp://hdl.handle.net/10185/19519
dc.description.abstractAntihistamínicos como el clorhidrato de epinastina tienen actividad antinflamatoria y podrían usarse como tratamiento del síndrome de ojo seco. Objetivo: evaluar los cambios en la sintomatología, película lagrimal y superficie ocular antes y después del tratamiento con clorhidrato de epinastina en pacientes con síndrome de ojo seco. Materiales y métodos: se realizó un estudio piloto doble ciego en 20 pacientes con diagnóstico clínico de ojo seco moderado. Un ojo de cada paciente recibió tratamiento con clorhidrato de epinastina al 0,05 % y el otro recibió hialuronato de sodio al 0,4 %. Los dos ojos recibieron suplemento lagrimal con hialuronato de sodio al 0,4 %. La dosis de tratamiento fue una gota tres veces al día por 45 días. Antes del tratamiento y 30 y 45 días después, se aplicó cuestionario validado para ojo seco (osdi), test de Schirmer 1, but y lisamina verde. Se aplicó la prueba t de Student y rangos de Wilcoxon. Resultados: se encontró un mejoría estadísticamente significativa en sintomatología a los 30 días de intervención con epinastina (p = 0,000) y 45 días (p = 0,0000). En la superficie ocular hubo mejoría clínica y significativa estadísticamente a los 45 días (p = 0,0001). No se encontraron cambios significativos en la calidad ni en la cantidad de la película lagrimal. La reducción en la sintomatología y el grado de tinción con la epinastina a los 45 días fue estadísticamente significativa (p < 0,05) con respecto al grupo control. Conclusión: la combinación clorhidrato de epinastina al 0,05% y hialuronato de sodio al 0,4% mejora la sintomatología y la superficie ocular en los pacientes con ojo seco moderado.spa
dc.description.abstractAntihistamines such as epinastine hydrochloride have anti-inflammatory activity and could be used as a treatment for dry eye syndrome. Objective: To assess changes in symptoms, tear film and ocular surface before and after treatment with epinastine hydrochloride in patients with dry eye syndrome. Materials and methods: A double-blind pilot study was carried out in 20 patients with clinical diagnosis of moderate dry eye. One eye of each patient was treated with 0.05% ofepinastine hydrochloride and the other received 0.4% of sodium hyaluronate. Both eyes received tear supplement with 0.4% of sodium hyaluronate. The treatment dose was one drop three times a day for 45 days. Before treatment and 30 and 45 days after, the validated questionnaire for dry eye (osdi), the Schirmer 1 Test, but and lissamine green were used. The Student’s t test and Wilcoxon ranges were used. Results: A statistically significant improvement in symptoms after 30 days of the intervention with epinastine was found (p = 0.000) and after 45 days (p = 0.0000). In the ocular surface there was clinically and statistically significant improvement after 45 days (p = 0.0001). No significant changes were found in quality or quantity of the tear film. The reduction in symptoms and in the degree of staining with epinastine after 45 days was statistically significant (p < 0.05) compared with the control group. Conclusion: The combination of epinastinehydrochloride 0.05% and sodium hyaluronate 0.4% improves symptoms and the ocular surface in patients with moderate dry eye.spa
dc.formatapplication/pdfspa
dc.languagespaspa
dc.publisherUniversidad de La Salle. Revistas. Ciencia y Tecnología para la Salud Visual y Ocular.spa
dc.relationhttp://revistas.lasalle.edu.co/index.php/sv/article/view/94/51spa
dc.relation/*ref*/Ankita, S., Bhavsar, S. G., y Sunita, M. (2011). A Review on Recent Advances in Dry Eye: Pathogenesis and Management. Oman Journal of Ophthalmology, 4 (2), 50- 56.spa
dc.relation/*ref*/Bachelet, I., Levi- S chaffer, F., y Mekori, Y. A. (2006). Mast Cells: Not Only in Allergy. Immunology and Allergy Clinical North American, 26 (3), 407- 425.spa
dc.relation/*ref*/Bouhlal, H., Blondin, C., Haeffner- Cavaillon, N., y Goldschmidt, P. (2002). N Acetyl- Aspartyl Glutamic Acid (Naaga) Inhibits the Adhesion of Leukocytes to Activated Endothelial Cells and Down- M odulates the Cytokine- Induced Expression of Adhesion Molecules. Journal French of Ophtalmology, 25 (10), 993-1000.spa
dc.relation/*ref*/Brignole- Baudolin, F., Robert, P. Y., Creuzot- Garcher, C., Olmiere, C., et ál. (2009). Evaluation of Naaga Efficacy in Dry Eye Syndrome. Journal Français d’Ophtalmologie, 32 (9), 613- 620.spa
dc.relation/*ref*/Brignole, F., Pisella, P. J., Goldschild, M., De Sanint Jean, M., Goguel, A., y Baudoin, C. (2000). Flow Cytometric Analysis of Inflammatory Markers in Conjunctival Epithelial Cells of Patients with Dry Eyes. Investigative in Ophthalmic and Vision Science, 41 (6), 1356- 1363.spa
dc.relation/*ref*/Church, M. K., y McGill, J. I. (2002). Human Ocular Mast Cells. Current Opinion Allergy Clinical Immunology, 2 (5), 419- 422.spa
dc.relation/*ref*/Corrales, R. M., Narayanan, S., Fernández, I., Mayo, A., Galarreta, D. J., Fuentes- Páez, G., Chaves, F. J., Herreras, J. M., y Calonge, M. (2011). Ocular Mucin Gene Expression Levels as Biomarkers for the Diagnosis of Dry Eye Syndrome. Investigative in Ophthalmic and Vision Science, 52 (11), 8363-8369.spa
dc.relation/*ref*/Dines, K. C., y Powell, H. C. (1997). Mast Cell Interactions with the Nervous System: Relationship to Mechanisms of Disease. Journal Neuropathology Experimental Neurology, 56 (6), 627-640.spa
dc.relation/*ref*/Dry Eye Workshop International (dews) (2007). Report of the International Dry Eye Workshop. The Ocular Surface, 5 (2), 67- 204.spa
dc.relation/*ref*/Enríquez- de- S alamanca, A., Castellanos, E., Stern, M. E., Fernández, I., Carreño, E., García- Vázquez, C., Herreras, J. M., y Calonge, M. (2010). Tear Cytokine and Chemokine Analysis and Clinical Correlations in Evaporative- Type Dry Eye Disease. Molecular Vision, 19 (16), 862- 873.spa
dc.relation/*ref*/Fox, R. I., Howell, F. V., Bone, R. C., y Michelson, P. (1984). Primary Sjögren Syndrome: Clinical and Immmunopathology Fatures. Seminars in Arthritis and Rheumatism, (14), 77- 105.spa
dc.relation/*ref*/Galatowicz, G., Ajayi, Y., Stern, M. E., y Calder V. L. (2007). Ocular Anti- Allergic Compounds Selectively Inhibit Human Mast Cell Cytokines in Vitro and Conjunctival cell Infiltration in Vivo. Clinical and Experimental Allergy, 37 (11), 1648- 1656.spa
dc.relation/*ref*/Galves, J. F., Lou, M. J., y Adreu, E. (1998). Ojos secos: diagnóstico y tratamiento. Información Terapéutica del Sistema Nacional de Salud, 22 (5), 117-122.spa
dc.relation/*ref*/Irani, A. M., Butrus, S. I., Tabbara, K. F., y Schwartz, L. B. (1990). Human Conjunctival Mast Cells: Distribution of mct and mctc in Vernal Conjunctivitis and Giant Papillary Conjunctivitis. Journal Allergy and Clinic Immunology, 86 (1), 34- 40.spa
dc.relation/*ref*/Johnson, M. E., Murphy, P. J., y Boulton, M. (2008). Carbomer and Sodium Hyaluronate Eyedrops for Moderate Dry Eye Treatment. Optometry and Vision Science, 85 (8), 750-75 7.spa
dc.relation/*ref*/Kaplan, J. G., Rosenberg, R., Reinitz, E., Buchbinder, S., y Schaumburg, H. H. (1990). Peripheral Neuropathy in Sjogren’s Syndrome. Muscle Nerve, (13), 570-579.spa
dc.relation/*ref*/Lambiase, A., Micera, A., y Bonini, S. (2009). Multiple Action Agents and the Eye: Do They Really Stabilize Mast Cells? Current Opinion Allergy Clinical Immunology, 9 (5), 454- 465.spa
dc.relation/*ref*/Lekhanont, K., Park, C. Y., Combs, J. C., Suwan- Apichon, O., Rangsin, R., y Chuck, R. S. (2007). Effect of Topical Olopatadine and Epinastine in the Botulinum Toxin B- Induced Mouse Model of Dry Eye. Journal Ocular Pharmacology Therapy, 23 (1), 83- 88.spa
dc.relation/*ref*/Levin, L. A., Albert, D. M., y Johnson, D. (1993). Mast Cells in Human Optic Nerve. Investigative Ophthalmology & Visual Science, (34), 3147- 3153.spa
dc.relation/*ref*/Paul, W. (1998). Fundamental Immunology (4th ed.). New York: Lippincott- Raven. Pflugfelder, S. C., Tseng, S. C., Sanabria, O., Kell, H., García, C. G., Felix, C., Feuer, W., y Reis, B. L. (1998). Evaluation of Subjective Assessments and Objective Diagnostic Tests for Diagnosing Tear- Film Disorders Known to Cause Ocular Irritation. Cornea, 17 (1), 38- 56.spa
dc.relation/*ref*/Pradhan, S., Abhishek, K., y Mah, F. (2009). Epinastine: Topical Ophthalmic Second Generation Antihistamine without Significant Systemic Side Effects. Expert Opinion Drug Metabolic Toxicology, 5 (9), 1135- 1140.spa
dc.relation/*ref*/Rao, K. N., y Brown, M. A. (2008). Mast Cells: Multifaceted Immune Cells with Diverse Roles in Health and Disease. Annual N.Y. Academic Science, (1143), 83-104.spa
dc.relation/*ref*/Reinoso, R., Calonge, M., Castellanos, E., Martino, M., Fernández, I., Stern, M. E., y Corell, A. (2011). Differential Cell Proliferation, Apoptosis, and Immune Response in Healthy and Evaporative- Type Dry Eye Conjunctival Epithelia. Investigative Ophthalmology and Visual Science, 52 (7), 4819- 4828.spa
dc.relation/*ref*/Rocha, E. M., Alves, M., Ríos, J. D., y Dartt, D. A. (2008). The Aging Lacrimal Gland: Changes in Structure and Function. The Ocular Surface, 6 (4), 162- 174.spa
dc.relation/*ref*/Schaumberg, D., Sullivan, D., Buring, J., y Dana, M. (2003). Prevalence of Dry Eye Syndrome Among US Women. Journal American of Ophthalmology, (136), 318- 326.spa
dc.relation/*ref*/Solomon, A., Dursun, D., Liu, Z., Xie, Y., Macri, A., y Plugfelder, S. C. (2001). Pro and Anti- Inflammatory Forms of Interleukin- 1 in the Tear Fluid and Conjunctiva of Patients with Dry Eye Disease. Investigative Ophthalmology & Visual Science, 42 (10), 2283-2292.spa
dc.relation/*ref*/Stern, M. E., Gao, J., Schwalb, T. A., Ngo, M., Tieu, D. D., Chan, C. C., Reis, B. L., Whitcup, S. M., Thompson, D., y Smith, J. A. (2002). Conjunctival T- Cell Subpopulations in Sjögren’s and Non- S jögren’s Patients with Dry Eye. Investigative Ophthalmology and Visual Science, 43 (8), 2609- 2614.spa
dc.relation/*ref*/Vico, E., Quereda, A., Benítez- Del- Castillo, J. M., Fernández, C., y García- Sánchez, J. (2005). A Comparative Study of 0.15 % Sodium Hyaluronate versus Polyvinyl Alcohol in the Treatment of Dry Eyes. Archives Society Española Ophthalmology, 80 (7), 387- 394.spa
dc.relation/*ref*/Villareal, A., Farley, W., y Pflugflder, S. (2007). Effect of Topical Ophthalmic Epinastine and Olopatadine on Tear Volume in Mice. Eye & Contact Lens, 32 (6), 272-276.spa
dc.relation/*ref*/Vogel, R., Crockett, R. S., Oden, N., Laliberte, T. W., y Molina, L. (2010). Demonstration of Efficacy in the Treatment of Dry Eye Disease with 0.18 % Sodium Hyaluronate Ophthalmic Solution (Vismed, Rejena). American Journal of Ophthalmology, 149 (4), 594-601.spa
dc.relation/*ref*/Williams, R. M., Singh, J., y Sharkey, K. A. (1994). Innervation and Mast Cells of the Rat Exorbital Gland: The Effects of Age. Journal Autonomo Nervios System, (47), 95-108.spa
dc.relation/*ref*/Yao, L., Baltatzis, S., Zafirakis, P., Livir- Rallatos, C., Voudouri,A., Markomichelakis, N., Zhao, T., y Foster, C. S. (2003). Human Mast Cell Subtypes in Conjunctiva of Patients with Atopic Keratoconjunctivitis, Ocular Cicatricial Pemphigoid and Stevens- Johnson Syndrome. Ocular Immunology Inflamation, 11 (3), 211-222.spa
dc.rightsCopyright (c) 2016 Universidad de La Sallespa
dc.rightshttps://creativecommons.org/licenses/by-nc/4.0/deed.esspa
dc.subjectClorhidrato de epinastina; hialuronato de sodio; schirmer 1; but; lisamina verde; película lagrimal; tinción superficie ocular; osdi; ojo secospa
dc.subjectEpinastine hydrochloride; sodium hyaluronate; schirmer 1; but; lissamine green; tear film; ocular surface staining; osdi; dry eyespa
dc.titleTratamiento con clorhidrato de epinastina al 0,05 % en pacientes con síndrome de disfunción lagrimal moderadospa
dc.titleTreatment with Epinastine Hydrochloride to 0.05 % in Patients with Moderate Tear Dysfunction Syndromespa
dc.typeinfo:eu-repo/semantics/articlespa
dc.typeinfo:eu-repo/semantics/publishedVersionspa
dc.rights.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/spa


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record